<DOC>
	<DOC>NCT01400919</DOC>
	<brief_summary>The DURABILITY Iliac study is a prospective, multi-center, non-randomized study confirming the safety and effectiveness of stenting using the Protégé® EverFlex™ and Protégé® GPS™ Self-Expanding Stent Systems for the treatment of atherosclerotic lesions in the common and/or external iliac arteries.</brief_summary>
	<brief_title>DURABILITY™ Iliac Study</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Menthol</mesh_term>
	<criteria>Patient has claudication as defined by a Rutherford Clinical Category Score of 2, 3 or 4. Evidence of ≥ 50% stenosis, restenosis or occlusion of target lesion(s) located in the common iliac artery and/or external iliac artery. Willing to comply with all followup evaluations at the specified times. Provides written informed consent prior to enrollment in the study. Previous implantation of stent(s) in the target vessel. Received endovascular treatment of the target lesion within six months prior to the index procedure. Known hypersensitivity to contrast material that cannot be adequately pretreated. Known hypersensitivity to nickeltitanium. Life expectancy of less than 12 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Peripheral arterial disease</keyword>
	<keyword>claudication</keyword>
	<keyword>stent</keyword>
	<keyword>EverFlex</keyword>
	<keyword>GPS</keyword>
	<keyword>Iliac Artery</keyword>
</DOC>